title: [Research progress on current pharmacokinetic evaluation of Chinese herbal medicines].
abstract: In order to prove safety and efficacy, herbal medicines must undergo the rigorous scientific researches such as pharmacokinetic and bioavailability, before they are put on the market in the foreign countries. Botanical Drug Products promulgated by the US FDA could guide industry sponsors to develop herbal drugs, which was also an important reference for investigating Chinese herbal medicines. This paper reviews and discusses novel approaches for how to assess systemic exposure and pharmacokinetic of Chinese herbal medicines, which were in line with FDA guidance. This mainly focus on identifying pharmacokinetic markers of botanical products, integral pharmacokinetic study of multiple components, Biopharmaceutics drug disposition classification system, and population pharmacokinetic-pharmacodynamic study in herb-drug interaction.
authors.affiliation: Department of pharmaceutics of Traditional Chinese Medicines, China Pharmaceutical University, Nanjing 210009, China.
authors.forename: Guofu
authors.initials: G
authors.lastname: Li
authors.forename: Haoru
authors.initials: H
authors.lastname: Zhao
authors.forename: Jin
authors.initials: J
authors.lastname: Yang
mesh_terms: D000818:Animals; D054316:Biomarkers, Pharmacological; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000493:pharmacokinetics*; D041743:Herb-Drug Interactions; D029001:Herbal Medicine / Q000331:legislation & jurisprudence; D006801:Humans
chemical_list: D054316:Biomarkers, Pharmacological; D004365:Drugs, Chinese Herbal